Upload train.csv with huggingface_hub

train.csv

@@ -0,0 +1,1922 @@
+Text
+"1 
+ COVID -19 Epidemiological Update  
+Edition  163 published  19 January  2024 
+In this edition:   
+• Key highlights   
+• Global overview  
+• Hospitalizations and ICU admissions  
+• SARS -CoV-2 variants of interest and variants under monitoring  
+• WHO regional overviews   
+ 
+ 
+Key highlights  
+ 
+• G"
+"
+• Hospitalizations and ICU admissions  
+• SARS -CoV-2 variants of interest and variants under monitoring  
+• WHO regional overviews   
+ 
+ 
+Key highlights  
+ 
+• Globally, during the 28 -day period from 11  December 2023  to 7 January 2024 , 106 countries report ed COVID -
+19 cases and 51"
+"lobally, during the 28 -day period from 11  December 2023  to 7 January 2024 , 106 countries report ed COVID -
+19 cases and 51 countries  report ed COVID -19 deaths. Note  that this does not reflect the actual number of 
+countries where cases or deaths are occurring , as many  countries have stopped or changed frequency of 
+reporting ."
+"countries  report ed COVID -19 deaths. Note  that this does not reflect the actual number of 
+countries where cases or deaths are occurring , as many  countries have stopped or changed frequency of 
+reporting .  
+• From the available data , the number of reported cases has increased while deaths have decreased during 
+the 28 -day period , with over 1.1 million new cases and 8700  new death"
+" 
+• From the available data , the number of reported cases has increased while deaths have decreased during 
+the 28 -day period , with over 1.1 million new cases and 8700  new deaths , an increase of 4% and a decrease 
+of 26%, respectively, compared to the previous 28 days ( 13 November to 10 December 2023 ). Trends in the 
+"
+"s , an increase of 4% and a decrease 
+of 26%, respectively, compared to the previous 28 days ( 13 November to 10 December 2023 ). Trends in the 
+number of reported new cases and deaths should be interpreted with caution due to decreased testing  and 
+sequencing, alongside reporting delays in many countries.   According  to estimates obtained from wastewater 
+surveillance,"
+"number of reported new cases and deaths should be interpreted with caution due to decreased testing  and 
+sequencing, alongside reporting delays in many countries.   According  to estimates obtained from wastewater 
+surveillance, clinical detection of cases underestimates  the real burden from 2 to 19 -fold.  
+• SARS -CoV-2 PCR percent positivity , as detected in integrated sentinel  surve"
+"clinical detection of cases underestimates  the real burden from 2 to 19 -fold.  
+• SARS -CoV-2 PCR percent positivity , as detected in integrated sentinel  surveillance  as part of  the Global 
+Influenza  Surveillance and Response System ( GISRS ) and reported to FluNet  was around 8 % as of 7 January 
+2024"
+"illance  as part of  the Global 
+Influenza  Surveillance and Response System ( GISRS ) and reported to FluNet  was around 8 % as of 7 January 
+2024. 
+• During the 28 -day period  from 11 December 2023  to 7 January , 53 and 42 countries provided  data at least 
+once on COVID -19"
+". 
+• During the 28 -day period  from 11 December 2023  to 7 January , 53 and 42 countries provided  data at least 
+once on COVID -19 hospitalizations and admissions to an intensive care unit (ICU) , respectively . From the 
+available data, over  173 000 new hospitalizations and over 1900 new ICU admissions were"
+"hospitalizations and admissions to an intensive care unit (ICU) , respectively . From the 
+available data, over  173 000 new hospitalizations and over 1900 new ICU admissions were reported  during 
+the 28 -day period .  Amongst  the countries reporting these data consistently over the current and past 
+reporting period, there was an overall increase  of 40% and 13"
+"reported  during 
+the 28 -day period .  Amongst  the countries reporting these data consistently over the current and past 
+reporting period, there was an overall increase  of 40% and 13% in new hospitalizations  and new ICU 
+admissions , respectively .  
+•  Globally, JN.1 is the most reported VOI (now reported by 71 countries), accounting for "
+"% in new hospitalizations  and new ICU 
+admissions , respectively .  
+•  Globally, JN.1 is the most reported VOI (now reported by 71 countries), accounting for 65.5% of sequences 
+in week 52 compared to 24.8% in week 48 (Figure 10, Table 6). Its parent lineage, BA.2.86"
+"65.5% of sequences 
+in week 52 compared to 24.8% in week 48 (Figure 10, Table 6). Its parent lineage, BA.2.86, is stable and 
+accounted for 7.8% of sequences in week 52 c ompared to 7.0% in week 48 (Figure 10, Table 6). The initial "
+", is stable and 
+accounted for 7.8% of sequences in week 52 c ompared to 7.0% in week 48 (Figure 10, Table 6). The initial 
+risk evaluation for JN.1  was published on 19 December 2023, with an overall evaluation of low public health 
+risk at the global level based on available evidence.  WHO is currently tracking"
+"
+risk evaluation for JN.1  was published on 19 December 2023, with an overall evaluation of low public health 
+risk at the global level based on available evidence.  WHO is currently tracking several SARS -CoV-2 variants : 
+five VOIs  – XBB.1.5, XBB.1.16 , EG.5  BA.2.86  and JN"
+"several SARS -CoV-2 variants : 
+five VOIs  – XBB.1.5, XBB.1.16 , EG.5  BA.2.86  and JN.1 ; and five VUMs : DV.7, XBB, XBB.1.9.1, XBB .1.9.2 and 
+XBB.2.3   
+• The Global WHO"
+".1 ; and five VUMs : DV.7, XBB, XBB.1.9.1, XBB .1.9.2 and 
+XBB.2.3   
+• The Global WHO Coronavirus (COVID -19) Dashboard  has been updated and adapted with a new interface 
+on 22 December 2023 to support WHO and Member States’ work to transition from COVID -"
+"Coronavirus (COVID -19) Dashboard  has been updated and adapted with a new interface 
+on 22 December 2023 to support WHO and Member States’ work to transition from COVID -19 as an 
+emergency to longer -term disease management, as outlined in WHO’s 3 May 2023 COVID -19 2023 -2025 
+Updated Strateg"
+"19 as an 
+emergency to longer -term disease management, as outlined in WHO’s 3 May 2023 COVID -19 2023 -2025 
+Updated Strategic Preparedness and Response Plan . The new dashboard will progressively incorporate more 
+components throughout 2024.  The previous link of the Global WHO Coronavirus (COVID -19) D"
+"ic Preparedness and Response Plan . The new dashboard will progressively incorporate more 
+components throughout 2024.  The previous link of the Global WHO Coronavirus (COVID -19) Dashboard will 
+still be active and redirect users  to the new one from 22 December onward. Please note that start time of 
+the redirection can differ around the world by up to 24 hours.  "
+"ashboard will 
+still be active and redirect users  to the new one from 22 December onward. Please note that start time of 
+the redirection can differ around the world by up to 24 hours.  
+ 
+ 2 
+  
+For t he latest data and other updates on COVID -19, please see:  
+• WHO Monthly Operational Update  and past editions of the Weekly  Epidemiological"
+"
+ 
+ 2 
+  
+For t he latest data and other updates on COVID -19, please see:  
+• WHO Monthly Operational Update  and past editions of the Weekly  Epidemiological Update on COVID -19 
+• WHO COVID -19 detailed surveillance data dashboard   
+• WHO COVID -19 policy briefs   
+• COVID -19 surveillance reporting requirements update for Member States"
+"Update on COVID -19 
+• WHO COVID -19 detailed surveillance data dashboard   
+• WHO COVID -19 policy briefs   
+• COVID -19 surveillance reporting requirements update for Member States  
+• Summary  Tables  of COVID -19 vaccine effectiveness (VE) studies and results (last updated 11 January 
+2024)  
+• Forest Plots  displaying results of COVID"
+" 
+• Summary  Tables  of COVID -19 vaccine effectiveness (VE) studies and results (last updated 11 January 
+2024)  
+• Forest Plots  displaying results of COVID -19 VE studies (last updated 15 January 2024)  
+• Special focus WEU on interpreting relative VE  (29 June 2022, pages 6 -8)"
+"-19 VE studies (last updated 15 January 2024)  
+• Special focus WEU on interpreting relative VE  (29 June 2022, pages 6 -8) 
+• Neutralizat ion p lots (last updated 15 January 2024)  
+• WHO COVID -19 VE Resources  
+ 
+ 
+Global overview  
+ 
+Data"
+"
+• Neutralizat ion p lots (last updated 15 January 2024)  
+• WHO COVID -19 VE Resources  
+ 
+ 
+Global overview  
+ 
+Data  as of 7 January  2024 
+Globally, the number of new weekly cases remained stable during the 28 -day period of 11 December 2023 to 7 
+J"
+" as of 7 January  2024 
+Globally, the number of new weekly cases remained stable during the 28 -day period of 11 December 2023 to 7 
+January 2024 as compared to the previous 28 -day period, with over 1.1 million new cases reported (Figure 1, 
+Table 1). The number of new weekly deaths "
+"anuary 2024 as compared to the previous 28 -day period, with over 1.1 million new cases reported (Figure 1, 
+Table 1). The number of new weekly deaths  decreased by 26% as compared to the previous 28 -day period, with 
+8700  new fatalities reported. As of 7 January 2024, over 774 million confirmed"
+"decreased by 26% as compared to the previous 28 -day period, with 
+8700  new fatalities reported. As of 7 January 2024, over 774 million confirmed cases and over 7 million deaths 
+have been reported globally.  According to estimates obtained from viral loads in wastewater surveillance, clinical 
+detection of cases underestimated the real burden "
+"cases and over 7 million deaths 
+have been reported globally.  According to estimates obtained from viral loads in wastewater surveillance, clinical 
+detection of cases underestimated the real burden 2 to 19 -fold1,2,3 
+Reported cases do not accurately represent infection rates due to the r eduction in testing and reporting globally . 
+During this 28 -day period"
+"2 to 19 -fold1,2,3 
+Reported cases do not accurately represent infection rates due to the r eduction in testing and reporting globally . 
+During this 28 -day period, only 45% (10 6 of 234) of countries reported at least one case to WHO. It is important 
+to note that this statistic does not reflect the actual number of countries where cases exist"
+", only 45% (10 6 of 234) of countries reported at least one case to WHO. It is important 
+to note that this statistic does not reflect the actual number of countries where cases exist. Additionally, data 
+from the previous 28 -day period are continuously being updated to inc orporate retrospective changes made by 
+countries regarding reported COVID -19 cases and deaths. Data presented in this"
+". Additionally, data 
+from the previous 28 -day period are continuously being updated to inc orporate retrospective changes made by 
+countries regarding reported COVID -19 cases and deaths. Data presented in this report are therefore incomplete 
+and should be interpreted considering these limitations. Some countries continue to r eport high burdens of 
+COVID -19, including increases in newly reported cases and, more importantly, increases in hospitalizations and"
+"report are therefore incomplete 
+and should be interpreted considering these limitations. Some countries continue to r eport high burdens of 
+COVID -19, including increases in newly reported cases and, more importantly, increases in hospitalizations and 
+deaths – the latter of which are considered more reliable indicators given reductions in testing. Global and 
+national data on SARS -CoV-2 PCR percent positivity are available on WHO’s"
+"
+deaths – the latter of which are considered more reliable indicators given reductions in testing. Global and 
+national data on SARS -CoV-2 PCR percent positivity are available on WHO’s integrated influenza and other 
+respiratory viruses surveillance dashboard . Recent data (epidemiological week one, 1 to 7 January  2024) from 
+sentinel sites show that"
+"integrated influenza and other 
+respiratory viruses surveillance dashboard . Recent data (epidemiological week one, 1 to 7 January  2024) from 
+sentinel sites show that the SARS -CoV-2 PCR percent positivity from reporting countries averages approximately 
+8% (Figure 2).   
+As many countries discontinue COVID -19-specific reporting and integrate it into respir"
+"the SARS -CoV-2 PCR percent positivity from reporting countries averages approximately 
+8% (Figure 2).   
+As many countries discontinue COVID -19-specific reporting and integrate it into respiratory disease surveillance, 
+WHO will use all available sources to continue monitoring the COVID -19 epidemiological situation, especially 
+data on morbidity and impact on h ealth systems. COVID -19 remains"
+"atory disease surveillance, 
+WHO will use all available sources to continue monitoring the COVID -19 epidemiological situation, especially 
+data on morbidity and impact on h ealth systems. COVID -19 remains a major threat, and WHO urges Member 
+States to maintain, not dismantle, their established COVID -19 infrastructure. It is crucial to sustain, inter alia , 
+early warning,"
+"a major threat, and WHO urges Member 
+States to maintain, not dismantle, their established COVID -19 infrastructure. It is crucial to sustain, inter alia , 
+early warning, surveillance and reporting, variant tracking, early clin ical care provision, administration of vaccine 
+to high -risk groups, improvements in ventilation, and regular communication.  
+ 
+1  Show us the data:"
+"surveillance and reporting, variant tracking, early clin ical care provision, administration of vaccine 
+to high -risk groups, improvements in ventilation, and regular communication.  
+ 
+1  Show us the data: global COVID -19 wastewater monitoring effectors, equity,  and gaps   
+ 
+2.  Capturing the SARS -CoV-2 infection pyramid within the municipality of Rotterdam using longitud"
+"global COVID -19 wastewater monitoring effectors, equity,  and gaps   
+ 
+2.  Capturing the SARS -CoV-2 infection pyramid within the municipality of Rotterdam using longitudinal sewage surveillance   
+ 
+3. Omicron COVID -19 Case Estimates Based on Previous SARS -CoV-2 Wastewater Load, Regional Municipality of Peel, Ontario,"
+"inal sewage surveillance   
+ 
+3. Omicron COVID -19 Case Estimates Based on Previous SARS -CoV-2 Wastewater Load, Regional Municipality of Peel, Ontario, Canada   
+ 3 
+ Current trends in reported COVID -19 cases and deaths should be interpreted with caution as several countries 
+have been progressively changing COVID -19 testing strategies, resulting in lower overall numbers of"
+"Canada   
+ 3 
+ Current trends in reported COVID -19 cases and deaths should be interpreted with caution as several countries 
+have been progressively changing COVID -19 testing strategies, resulting in lower overall numbers of tests 
+performed and consequently lower numbers o f cases detected. Additionally, data from previous weeks are 
+continuously updated to retrospectively incorporate changes in reported COVID -19 cases and deaths made by 
+count"
+"tests 
+performed and consequently lower numbers o f cases detected. Additionally, data from previous weeks are 
+continuously updated to retrospectively incorporate changes in reported COVID -19 cases and deaths made by 
+countries.  
+ 
+ 
+Figure 1. COVID -19 cases and global deaths by 28 -day intervals reported by WHO Region,  as of 7 January 2024 ( A); "
+"ries.  
+ 
+ 
+Figure 1. COVID -19 cases and global deaths by 28 -day intervals reported by WHO Region,  as of 7 January 2024 ( A); 26 
+June  to 17 January 2024 (B)** 
+ 
+ 
+ 
+ 
+**See Annex 1: Data, table, and figure note  
+ 
+A"
+"26 
+June  to 17 January 2024 (B)** 
+ 
+ 
+ 
+ 
+**See Annex 1: Data, table, and figure note  
+ 
+A 
+B 4 
+ At the regional level, the number of newly reported 28 -day cases decreased across four of the six WHO regions: 
+the African Region ( -63%), the Region of the Amer"
+"
+B 4 
+ At the regional level, the number of newly reported 28 -day cases decreased across four of the six WHO regions: 
+the African Region ( -63%), the Region of the Americas ( -18%), the Eastern Mediterranean Region ( -13%), and 
+the European Region ( -13%); while case  numbers increased in two WHO regions: the Western Pacific Region 
+(+"
+"icas ( -18%), the Eastern Mediterranean Region ( -13%), and 
+the European Region ( -13%); while case  numbers increased in two WHO regions: the Western Pacific Region 
+(+77%), and the South -East Asia Region (+379%). The number of newly reported 28 -day deaths decreased or 
+remained stable across five regions: the African Region ( -113%"
+"77%), and the South -East Asia Region (+379%). The number of newly reported 28 -day deaths decreased or 
+remained stable across five regions: the African Region ( -113%), the Eastern Mediterra nean Region ( -53%), the 
+Western Pacific Region ( -45%), the Region of the Americas ( -41%), and the European Region ( -3%); while death"
+"), the Eastern Mediterra nean Region ( -53%), the 
+Western Pacific Region ( -45%), the Region of the Americas ( -41%), and the European Region ( -3%); while death 
+numbers increased in the South -East Asia Region (+564%).  
+At the country level, the highest numbers of new 28 -day cases were reported from the Russian Federation (235 
+198"
+"
+numbers increased in the South -East Asia Region (+564%).  
+At the country level, the highest numbers of new 28 -day cases were reported from the Russian Federation (235 
+198 new cases; -30%), Singapore (174 643 new cases; +117%), Italy (163 599 new cases; -18%), Greece (68 59"
+"new cases; -30%), Singapore (174 643 new cases; +117%), Italy (163 599 new cases; -18%), Greece (68 590 
+new cases; +81%), and Malaysia (67 206 n ew cases; +164%). The highest numbers of new 28 -day deaths were 
+reported from Italy"
+"0 
+new cases; +81%), and Malaysia (67 206 n ew cases; +164%). The highest numbers of new 28 -day deaths were 
+reported from Italy (1016 new deaths; -21%), the Russian Federation (679 new deaths; +45%), Poland (543 new 
+deaths; +229%), Sweden ("
+"(1016 new deaths; -21%), the Russian Federation (679 new deaths; +45%), Poland (543 new 
+deaths; +229%), Sweden (446 new deaths; -47%), and Greece (322 new deaths; +79%).  
+ 
+Table 1. Newly reported and cumulative COVID -19 confirmed cases and deaths,"
+"446 new deaths; -47%), and Greece (322 new deaths; +79%).  
+ 
+Table 1. Newly reported and cumulative COVID -19 confirmed cases and deaths, by WHO Region, as of 7 January  2024** 
+WHO 
+Region  New cases in  
+last 28 days 
+(%) Change in 
+new cases in 
+last 2"
+"by WHO Region, as of 7 January  2024** 
+WHO 
+Region  New cases in  
+last 28 days 
+(%) Change in 
+new cases in 
+last 28 days *  Cumulative 
+cases (%)  New deaths 
+in  last 28 
+days (%)  Change in 
+new deaths 
+in last 28 
+days *  C"
+"8 days *  Cumulative 
+cases (%)  New deaths 
+in  last 28 
+days (%)  Change in 
+new deaths 
+in last 28 
+days *  Cumulative 
+deaths (%)  Countries 
+reporting 
+cases in the 
+last 28 days  Countries 
+reporting 
+deaths in 
+the last 28 
+"
+"umulative 
+deaths (%)  Countries 
+reporting 
+cases in the 
+last 28 days  Countries 
+reporting 
+deaths in 
+the last 28 
+days  
+Europe  701 053  
+  (63%)  -13%  278 615 
+939 
+  (36%)  4 194"
+"days  
+Europe  701 053  
+  (63%)  -13%  278 615 
+939 
+  (36%)  4 194  
+  (48%)  -3% 2 265 734  
+  (32%)  34/61  
+ (56%)  23/61  
+ (3"
+" 
+  (48%)  -3% 2 265 734  
+  (32%)  34/61  
+ (56%)  23/61  
+ (38%)  
+Western 
+Pacific  338 056  
+  (30%)  77%  208 014 
+763 
+  (27%)"
+"8%)  
+Western 
+Pacific  338 056  
+  (30%)  77%  208 014 
+763 
+  (27%)  416 
+  (5%)  -45%  419 274  
+  (6%)  17/35  
+ (49%)  8/35  
+(2"
+" 416 
+  (5%)  -45%  419 274  
+  (6%)  17/35  
+ (49%)  8/35  
+(23%)  
+America
+s 42 330  
+  (4%)  -18%  193 223 
+732 
+  (25%)  3 86"
+"3%)  
+America
+s 42 330  
+  (4%)  -18%  193 223 
+732 
+  (25%)  3 869  
+  (44%)  -41%  2 992 342  
+  (43%)  17/56  
+(30%)  9/56  
+("
+"9  
+  (44%)  -41%  2 992 342  
+  (43%)  17/56  
+(30%)  9/56  
+(16%)  
+South -
+East 
+Asia 26 469  
+  (2%)  379%  61 241 866  
+  (8%)"
+"16%)  
+South -
+East 
+Asia 26 469  
+  (2%)  379%  61 241 866  
+  (8%)  186 
+  (2%)  564%  808 278  
+  (12%)  6/10  
+ (60%)  4/10  
+(4"
+" 186 
+  (2%)  564%  808 278  
+  (12%)  6/10  
+ (60%)  4/10  
+(40%)  
+Africa  3 354  
+  (0%)  -63%  9 568 385  
+  (1%)  -2 
+  (0%)  -"
+"0%)  
+Africa  3 354  
+  (0%)  -63%  9 568 385  
+  (1%)  -2 
+  (0%)  -113%  175 473  
+  (3%)  28/50  
+ (56%)  4/50  
+ (8%)  
+Eastern 
+Mediter
+rane"
+"113%  175 473  
+  (3%)  28/50  
+ (56%)  4/50  
+ (8%)  
+Eastern 
+Mediter
+ranean  2 464  
+  (0%)  -13%  23 409 749  
+  (3%)  37 
+  (0%)  -53%  "
+"an  2 464  
+  (0%)  -13%  23 409 749  
+  (3%)  37 
+  (0%)  -53%  351 870  
+  (5%)  4/22  
+(18%)  3/22  
+ (14%)  
+Global  1 113 726  
+"
+"351 870  
+  (5%)  4/22  
+(18%)  3/22  
+ (14%)  
+Global  1 113 726  
+  (100%)  4%    774 075 
+198 
+  (100%)  8 700  
+  (100%)  -26%  "
+" (100%)  4%    774 075 
+198 
+  (100%)  8 700  
+  (100%)  -26%  7 012 984  
+  (100%)  106/234 
+(45%)  51/234 
+(22%)  
+ 
+*Percent"
+"7 012 984  
+  (100%)  106/234 
+(45%)  51/234 
+(22%)  
+ 
+*Percent change in the number of newly confirmed cases/deaths in the past 28 days, compared to 28 days prior. Data from previous weeks are 
+updated continuously with adjustments received from countries.  
+**See Anne"
+"change in the number of newly confirmed cases/deaths in the past 28 days, compared to 28 days prior. Data from previous weeks are 
+updated continuously with adjustments received from countries.  
+**See Annex 1: Data, table, and figure notes                                                                                                                                                                     
+ 
+ 
+ 
+ 
+ 5 
+ Figure 2. SARS -CoV-2 specimens"
+"x 1: Data, table, and figure notes                                                                                                                                                                     
+ 
+ 
+ 
+ 
+ 5 
+ Figure 2. SARS -CoV-2 specimens tested and test positivity rates reported to FluNet  from sent inel sites ; 5 January 
+2020 to 7 January  2024 
+ 
+ 
+ 
+Source: Influenza"
+"tested and test positivity rates reported to FluNet  from sent inel sites ; 5 January 
+2020 to 7 January  2024 
+ 
+ 
+ 
+Source: Influenza and SARS -CoV-2 surveillance data from GISRS  reported to FluNet ; WHO Global Influenza Programme
+ 
+6 
+ Figure 3. Number of confirmed  COVID -1"
+"and SARS -CoV-2 surveillance data from GISRS  reported to FluNet ; WHO Global Influenza Programme
+ 
+6 
+ Figure 3. Number of confirmed  COVID -19 cases  reported over  the last 28 days per 100 000 population , as of 7 January  2024** 
+ 
+**See Annex 1: Data, table, and"
+"9 cases  reported over  the last 28 days per 100 000 population , as of 7 January  2024** 
+ 
+**See Annex 1: Data, table, and figure notes  
+ 
+7 
+ Figure 4. Percentage change in confirmed COVID -19 cases  over the last 28 days relative to the previous 28 days, as of 7 January  202"
+"figure notes  
+ 
+7 
+ Figure 4. Percentage change in confirmed COVID -19 cases  over the last 28 days relative to the previous 28 days, as of 7 January  2024** 
+ 
+**Se e Annex 1: Data, table, and figure notes  
+ 
+8 
+ Figure  5. Number  of COVID -19 deaths  reported over  the last 28"
+"4** 
+ 
+**Se e Annex 1: Data, table, and figure notes  
+ 
+8 
+ Figure  5. Number  of COVID -19 deaths  reported over  the last 28 days per 100 000 population , as of 7 January   2024 ** 
+ 
+**Se e Annex 1: Data, table, and figure notes  
+ 
+9 
+ Figure"
+"days per 100 000 population , as of 7 January   2024 ** 
+ 
+**Se e Annex 1: Data, table, and figure notes  
+ 
+9 
+ Figure 6. Percentage change in confirmed COVID -19 deaths  over the last 28 days relative to the previous 28 days, as of 7 January  2024** 
+ 
+**Se e"
+"6. Percentage change in confirmed COVID -19 deaths  over the last 28 days relative to the previous 28 days, as of 7 January  2024** 
+ 
+**Se e Annex 1: Data, table, and figure notes  
+ 
+10 
+  
+Hospitalizations and ICU admissions  
+ 
+At the global level, during the past 28 days (11 December"
+"Annex 1: Data, table, and figure notes  
+ 
+10 
+  
+Hospitalizations and ICU admissions  
+ 
+At the global level, during the past 28 days (11 December 2023  to 7 January 2024), a total of 173 547  new 
+hospitalizations and 1 966 new intensive care unit (ICU)"
+"2023  to 7 January 2024), a total of 173 547  new 
+hospitalizations and 1 966 new intensive care unit (ICU) admissions were reported from 5 3 and 4 2 countries, 
+respectively (Figure 7). This represents 32% increase and 3% decrease, respectively, compared to the previous 28 "
+"admissions were reported from 5 3 and 4 2 countries, 
+respectively (Figure 7). This represents 32% increase and 3% decrease, respectively, compared to the previous 28 
+days (13 November to 10 December 2023). Note that the absence of reported data from some countries to WHO 
+does not imply that there are no COVID -19-related hospitalizations in those countries"
+"
+days (13 November to 10 December 2023). Note that the absence of reported data from some countries to WHO 
+does not imply that there are no COVID -19-related hospitalizations in those countries. The prese nted hospitalization 
+data are preliminary and might change as new data become available. Furthermore, hospitalization data are subject 
+to reporting delays. These data also likely include both hospitalizations with incidental cases"
+". The prese nted hospitalization 
+data are preliminary and might change as new data become available. Furthermore, hospitalization data are subject 
+to reporting delays. These data also likely include both hospitalizations with incidental cases of SARS -CoV-2 infection 
+and those due to COVID -19 disease.   
+  
+ 
+New hospitalizations  
+During the past 28 days, 5 3 (23"
+"of SARS -CoV-2 infection 
+and those due to COVID -19 disease.   
+  
+ 
+New hospitalizations  
+During the past 28 days, 5 3 (23%) countries reported data to WHO on new hospitalizations at least once (Figure 7). 
+The Region of the Americas had the highest proportion of countries reporting data on new hospitalizations (1 9 
+countries; "
+"%) countries reported data to WHO on new hospitalizations at least once (Figure 7). 
+The Region of the Americas had the highest proportion of countries reporting data on new hospitalizations (1 9 
+countries; 3 4%), followed by the European Region (15 countries; 25%), the African Region (12 countries; 24%), the 
+South -East Asia Region (two countries; 20"
+"3 4%), followed by the European Region (15 countries; 25%), the African Region (12 countries; 24%), the 
+South -East Asia Region (two countries; 20%), and the Western Pacific Region (five countries; 14%). No country in the 
+Eastern Mediterranean Region shared1. The number of countries that consistently reported new hospitalizations 
+for the period was 9"
+"%), and the Western Pacific Region (five countries; 14%). No country in the 
+Eastern Mediterranean Region shared1. The number of countries that consistently reported new hospitalizations 
+for the period was 9% (22  countries) (Table 2).  
+ 
+Among the 22 countries consistently reporting new hospitalizations, 8 (36%) countries registered an increase of 20% 
+or greater in"
+"% (22  countries) (Table 2).  
+ 
+Among the 22 countries consistently reporting new hospitalizations, 8 (36%) countries registered an increase of 20% 
+or greater in hospitalizations during the past 28 days compared to the previous 28 -day period: Indonesia (1337 vs 
+149; +797%), Malta (79 vs 21;"
+"hospitalizations during the past 28 days compared to the previous 28 -day period: Indonesia (1337 vs 
+149; +797%), Malta (79 vs 21; +276%), Brunei Darussalam (588 vs 161; +265%),  Malaysia (9312 vs 4137; +125%),"
+"+276%), Brunei Darussalam (588 vs 161; +265%),  Malaysia (9312 vs 4137; +125%), 
+Greece (6366 vs 3792; +68%), Singapore (2619 vs 1719; +52%), United Sates of America (12 8"
+"
+Greece (6366 vs 3792; +68%), Singapore (2619 vs 1719; +52%), United Sates of America (12 8 073 vs 84 98 1; +51%), 
+and Ireland (1353 vs 967; +40%).  
+The highest numbers of new hospital admissions were reported"
+"073 vs 84 98 1; +51%), 
+and Ireland (1353 vs 967; +40%).  
+The highest numbers of new hospital admissions were reported from the United States of America (12 8 073  vs 84 
+981; +51%), Malaysia (9312 vs 4137; +125%"
+"from the United States of America (12 8 073  vs 84 
+981; +51%), Malaysia (9312 vs 4137; +125%), and Italy (8845 vs 13 857; -36%).  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+11 
+  
+Table"
+"), and Italy (8845 vs 13 857; -36%).  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+11 
+  
+Table 2. Number of new hospitalization admissions reported by WHO regions, 11 December 2023  to 7 January 2024  
+compared to 16 October to 13  November"
+"2. Number of new hospitalization admissions reported by WHO regions, 11 December 2023  to 7 January 2024  
+compared to 16 October to 13  November to 10 December 2023  
+Region  Countries reported at least once in 
+the past 28 days  Countries reported consistently in the past and 
+previous 28 days*  
+Number"
+"to 10 December 2023  
+Region  Countries reported at least once in 
+the past 28 days  Countries reported consistently in the past and 
+previous 28 days*  
+Number of 
+countries 
+(percentage)**  Number of new 
+hospitalizations  Number of 
+countries 
+(percentage)**  Number of new 
+hospitalizations  Percent change in "
+"of 
+countries 
+(percentage)**  Number of new 
+hospitalizations  Number of 
+countries 
+(percentage)**  Number of new 
+hospitalizations  Percent change in 
+new hospitalizations  
+Africa  12/50 (24%)  61 3/50 ( 6%)  6 -45%  
+Americas  19/56 (3 4"
+"
+new hospitalizations  
+Africa  12/50 (24%)  61 3/50 ( 6%)  6 -45%  
+Americas  19/56 (3 4%)  134 789  5/56 ( 9%)  129 408  +48%  
+Eastern   
+Mediterranean  0/22 (<1%)"
+"%)  134 789  5/56 ( 9%)  129 408  +48%  
+Eastern   
+Mediterranean  0/22 (<1%)  N/A***  0/22 (<1%)  N/A N/A 
+Europe  15/61 (25%)  23 039  9/61 (15%)"
+" N/A***  0/22 (<1%)  N/A N/A 
+Europe  15/61 (25%)  23 039  9/61 (15%)  22 574  -9%  
+South -East  
+Asia  2/10 (20%)  1358  2/10 (20%)  1358"
+" 22 574  -9%  
+South -East  
+Asia  2/10 (20%)  1358  2/10 (20%)  1358 +690%  
+Western   
+Pacific  5/35 (14%)  14 300  5/35 (14%)  14 300  +88"
+"+690%  
+Western   
+Pacific  5/35 (14%)  14 300  5/35 (14%)  14 300  +88%  
+Global  53/234 (2 3%)  173 547  24/234 ( 10%)  167 646 +40% 
+"
+"%  
+Global  53/234 (2 3%)  173 547  24/234 ( 10%)  167 646 +40% 
+ 
+*Percent change is calculated for countries reporting consistently both in the past 28 days and the previous 28 days (compari son period).  
+**Number of countries reported / total number of countries in the region ("
+"
+*Percent change is calculated for countries reporting consistently both in the past 28 days and the previous 28 days (compari son period).  
+**Number of countries reported / total number of countries in the region (percentage of reporting).  
+*** N/A represents not available  or applicable .  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+"
+"percentage of reporting).  
+*** N/A represents not available  or applicable .  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+12 
+  
+Table 3. Countries that consistently reported new hospitalizations by WHO region, 11  December 2023 to 7 January 2024 
+compared to 1"
+"12 
+  
+Table 3. Countries that consistently reported new hospitalizations by WHO region, 11  December 2023 to 7 January 2024 
+compared to 13 November to 10 December 2023.  
+WHO Region  Country  New Hospitalization in 
+past 28 days  New Hospitalization in 
+previous 28 -day period  % Change"
+"3 November to 10 December 2023.  
+WHO Region  Country  New Hospitalization in 
+past 28 days  New Hospitalization in 
+previous 28 -day period  % Change from 
+previous 28 -day 
+period  
+Africa  Mauritania  0 0 N/A  
+Africa  Mali  0 0 N/A  
+Africa  Angola  6"
+"from 
+previous 28 -day 
+period  
+Africa  Mauritania  0 0 N/A  
+Africa  Mali  0 0 N/A  
+Africa  Angola  6 11 -45%  
+Americas  Turks and Caicos Islands  0 0 N/A  
+Americas  United States of America  128073  84981  51"
+"11 -45%  
+Americas  Turks and Caicos Islands  0 0 N/A  
+Americas  United States of America  128073  84981  51%  
+Americas  Canada  1335  2685  -50%  
+Americas  Saint Lucia  0 7 -100%  
+Americas  Honduras  0 "
+"%  
+Americas  Canada  1335  2685  -50%  
+Americas  Saint Lucia  0 7 -100%  
+Americas  Honduras  0 5 -100%  
+Europe  Malta  79 21 276%  
+Europe  Greece  6366  3792  68%  
+Europe  Ireland  13"
+"5 -100%  
+Europe  Malta  79 21 276%  
+Europe  Greece  6366  3792  68%  
+Europe  Ireland  1353  967  40%  
+Europe  Netherlands  2474  2196  13%  
+Europe  Slovakia  925  1015  -9% "
+"53  967  40%  
+Europe  Netherlands  2474  2196  13%  
+Europe  Slovakia  925  1015  -9% 
+Europe  Czechia  2083  2317  -10%  
+Europe  Estonia  420  474  -11%  
+Europe  Italy  8845  "
+"
+Europe  Czechia  2083  2317  -10%  
+Europe  Estonia  420  474  -11%  
+Europe  Italy  8845  13857  -36%  
+Europe  Portugal  29 57 -49%  
+South -East Asia  Indonesia  1337  149  797%"
+"13857  -36%  
+Europe  Portugal  29 57 -49%  
+South -East Asia  Indonesia  1337  149  797%  
+South -East Asia  Bangladesh  21 23 -9% 
+Western Pacific  Brunei Darussalam  588  161  265%  
+West"
+" 
+South -East Asia  Bangladesh  21 23 -9% 
+Western Pacific  Brunei Darussalam  588  161  265%  
+Western Pacific  Malaysia  9312  4137  125%  
+Western Pacific  Singapore  2619  1719  52%  
+Western Pacific  New Zealand  "
+"ern Pacific  Malaysia  9312  4137  125%  
+Western Pacific  Singapore  2619  1719  52%  
+Western Pacific  New Zealand  1726  1484  16%  
+Western Pacific  Mongolia  55 106  -48%  
+ 
+*N/A represents not applicable                                                                                                "
+"1726  1484  16%  
+Western Pacific  Mongolia  55 106  -48%  
+ 
+*N/A represents not applicable                                                                                                                                                                                                                   
+ +WHO emphasizes the importance of maintaining reporting and encourages countries to report the absence of new admissions (“zero reporting”) if 
+there are no new hospital or ICU adm"
+"                                                                                                                  
+ +WHO emphasizes the importance of maintaining reporting and encourages countries to report the absence of new admissions (“zero reporting”) if 
+there are no new hospital or ICU admissions during the week.  
+ 
+ 
+ 
+  
+13 
+ New ICU admissions  
+Across the six WHO regions, in the past 28 days, a total of 4 2 ("
+"issions during the week.  
+ 
+ 
+ 
+  
+13 
+ New ICU admissions  
+Across the six WHO regions, in the past 28 days, a total of 4 2 (19%) countries reported data to WHO on new ICU 
+admissions at least once (Figure 8). The African Region had the highest proportion of countries reporting data on 
+new ICU admissions (13 countries"
+"19%) countries reported data to WHO on new ICU 
+admissions at least once (Figure 8). The African Region had the highest proportion of countries reporting data on 
+new ICU admissions (13 countries; 26%), followed by the European Region (12 countries; 20%), the Region of the 
+Americas (10 countries, 14%), the Western Pacific Region (six countries; 17"
+"; 26%), followed by the European Region (12 countries; 20%), the Region of the 
+Americas (10 countries, 14%), the Western Pacific Region (six countries; 17%) , and the South -East Asia Region (one 
+country; 10%). No country in the Eastern Mediterranean Region reported ICU data during the period. The 
+proportion of coun tries that consistently reported"
+"%) , and the South -East Asia Region (one 
+country; 10%). No country in the Eastern Mediterranean Region reported ICU data during the period. The 
+proportion of coun tries that consistently reported new ICU admissions for the period was 8% (1 8 countries). 
+Among the 1 8 countries consistently reporting new ICU admissions, eight ( 44%) countries showed an increase of 
+"
+"new ICU admissions for the period was 8% (1 8 countries). 
+Among the 1 8 countries consistently reporting new ICU admissions, eight ( 44%) countries showed an increase of 
+20% or greater in new ICU admissions during the past 28 days compared to the previous 28 -day period: Indonesia 
+(164 vs 18; +811%), Malaysia"
+"20% or greater in new ICU admissions during the past 28 days compared to the previous 28 -day period: Indonesia 
+(164 vs 18; +811%), Malaysia (135 vs 15; +800%), Singapore (77 vs38; +103%), Estonia (18 vs 10; +80%), Ireland  (20 "
+"(135 vs 15; +800%), Singapore (77 vs38; +103%), Estonia (18 vs 10; +80%), Ireland  (20 
+vs 13; +54%), Netherlands (120 vs 86; +40%), Greece (120 vs 88; +36%), and Czechia (18 2 vs"
+"
+vs 13; +54%), Netherlands (120 vs 86; +40%), Greece (120 vs 88; +36%), and Czechia (18 2 vs 146; +25%)  
+The highest numbers of new ICU admissions were reported from Italy (464 vs 492; -6%), Czechia (182 vs 146;"
+"146; +25%)  
+The highest numbers of new ICU admissions were reported from Italy (464 vs 492; -6%), Czechia (182 vs 146; 
++25%), and Indonesia (164 vs 18; +811%).  
+ 
+Table 4. Number of new ICU admissions reported by WHO regions, 11 December "
+"
++25%), and Indonesia (164 vs 18; +811%).  
+ 
+Table 4. Number of new ICU admissions reported by WHO regions, 11 December 2023 to 7 January 2024 compared   to  
+13 November  to 10 December  2023  
+WHO Region  Countries reported at least once 
+in the past "
+"2023 to 7 January 2024 compared   to  
+13 November  to 10 December  2023  
+WHO Region  Countries reported at least once 
+in the past 28 days  Countries reported consistently in the past and previous 28 
+days*  
+Number of 
+countries 
+(percentage)**  Number of 
+new ICU 
+admissions "
+"28 days  Countries reported consistently in the past and previous 28 
+days*  
+Number of 
+countries 
+(percentage)**  Number of 
+new ICU 
+admissions  Number of 
+countries 
+(percentage)**  Number of 
+new ICU 
+admissions  Percent change in 
+new ICU admissions  
+Africa  13/50 (2"
+"Number of 
+countries 
+(percentage)**  Number of 
+new ICU 
+admissions  Percent change in 
+new ICU admissions  
+Africa  13/50 (26%)  6 1/50 ( 2%)  0 N/A  
+Americas  10/56 (1 8%)  386 2/56 (16%)  99 -"
+"6%)  6 1/50 ( 2%)  0 N/A  
+Americas  10/56 (1 8%)  386 2/56 (16%)  99 -55%  
+Eastern   
+Mediterranean  0/22 (<1%)  N/A***  0/22 (<1%)  N/A N/A 
+Europe  12/"
+"55%  
+Eastern   
+Mediterranean  0/22 (<1%)  N/A***  0/22 (<1%)  N/A N/A 
+Europe  12/61 (20%)  1097  8/61 (1 3%)  1032  +3%  
+South -East  
+Asia  1/10 (10%)"
+"61 (20%)  1097  8/61 (1 3%)  1032  +3%  
+South -East  
+Asia  1/10 (10%)  164 1/10 (10%)  164 +811%  
+Western   
+Pacific  6/35 (17%)  313 6/35 ("
+" 164 1/10 (10%)  164 +811%  
+Western   
+Pacific  6/35 (17%)  313 6/35 ( 14%)  256 +86%  
+Global  42/235 (1 9%)  1966  18/235 ( 8%)  1551 +1"
+"14%)  256 +86%  
+Global  42/235 (1 9%)  1966  18/235 ( 8%)  1551 +13% 
+ 
+*Percent change is calculated for countries report ing consistently both in the past 28 days and the previous 28 days (comparison period).  
+**Number of countries reported / total number of countries in"
+"3% 
+ 
+*Percent change is calculated for countries report ing consistently both in the past 28 days and the previous 28 days (comparison period).  
+**Number of countries reported / total number of countries in the region (percentage of reporting).  
+*** N/A represents data not available  or applicable .  
++ WHO emphasizes the importance of maintaining reporting and encourages countries to report the absence of new admissions (“zero"
+"the region (percentage of reporting).  
+*** N/A represents data not available  or applicable .  
++ WHO emphasizes the importance of maintaining reporting and encourages countries to report the absence of new admissions (“zero re porting”) if 
+there are no new hospital or ICU admissions during the week.  
+  
+14 
+ Table 5. Countries that consistently reported new ICU admissions  by WHO regions"
+"re porting”) if 
+there are no new hospital or ICU admissions during the week.  
+  
+14 
+ Table 5. Countries that consistently reported new ICU admissions  by WHO regions, 11  December 2023 to 7 January 2024 
+compared to 13 November to 10 December 2023.  
+WHO Region   Country  New IC"
+", 11  December 2023 to 7 January 2024 
+compared to 13 November to 10 December 2023.  
+WHO Region   Country  New ICU admissions in 
+past 28 days  New ICU admissions in 
+previous 28 days  % Change in ICU 
+admissions from 
+previous 28 -day period  
+A"
+"U admissions in 
+past 28 days  New ICU admissions in 
+previous 28 days  % Change in ICU 
+admissions from 
+previous 28 -day period  
+Africa   Mauritania  0 0 N/A 
+Americas   Canada  99 221 -55% 
+Americas  Honduras  0 0 N/A 
+Europe   Italy  "
+"frica   Mauritania  0 0 N/A 
+Americas   Canada  99 221 -55% 
+Americas  Honduras  0 0 N/A 
+Europe   Italy  464 492 -6% 
+Europe   Czechia  182 146 25%  
+Europe   Netherlands  120 86 40%  
+Europe   Greece  "
+"464 492 -6% 
+Europe   Czechia  182 146 25%  
+Europe   Netherlands  120 86 40%  
+Europe   Greece  120 88 36%  
+Europe   Sweden  101 158 -36%  
+Europe   Ireland  20 13 54%  
+Europe   Estonia  1"
+"120 88 36%  
+Europe   Sweden  101 158 -36%  
+Europe   Ireland  20 13 54%  
+Europe   Estonia  18 10 80%  
+Europe   Slovakia  7 9 -22%  
+South -East Asia   Indonesia  164 18 811%  
+Western"
+"8 10 80%  
+Europe   Slovakia  7 9 -22%  
+South -East Asia   Indonesia  164 18 811%  
+Western Pacific   Malaysia  135 15 800%  
+Western Pacific   Singapore  77 38 103%  
+Western Pacific   New Zealand  39 38 3"
+"Pacific   Malaysia  135 15 800%  
+Western Pacific   Singapore  77 38 103%  
+Western Pacific   New Zealand  39 38 3% 
+Western Pacific   Brunei Darussalam  5 5 0% 
+Western Pacific   Mongolia  0 0 N/A 
+Western Pacific  Australia  163 22"
+"% 
+Western Pacific   Brunei Darussalam  5 5 0% 
+Western Pacific   Mongolia  0 0 N/A 
+Western Pacific  Australia  163 220 -26%  
+ 
+* N/A represents not applicable + WHO emphasizes the importance of maintaining reporting and encourages countries to report the absence of new 
+admissions (“zero reporting”) if there"
+"0 -26%  
+ 
+* N/A represents not applicable + WHO emphasizes the importance of maintaining reporting and encourages countries to report the absence of new 
+admissions (“zero reporting”) if there are no new hospital or ICU admissions during the week.  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+15 
+ Figure 7.  28 -day global COVID -1"
+"are no new hospital or ICU admissions during the week.  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+15 
+ Figure 7.  28 -day global COVID -19 new hospitalizations and ICU admissions, from 3 February 2020  to 7 January 
+2024  (A); and  from 1 May  2023 to 7 January "
+"9 new hospitalizations and ICU admissions, from 3 February 2020  to 7 January 
+2024  (A); and  from 1 May  2023 to 7 January 2024  (B) 
+   A 
+ 
+ 
+B 
+ 
+ 
+ 
+Note: Recent weeks are subject to reporting delays and data might not be complete, thus the data should be"
+"2024  (B) 
+   A 
+ 
+ 
+B 
+ 
+ 
+ 
+Note: Recent weeks are subject to reporting delays and data might not be complete, thus the data should be  interpret ed with caution. Cases included 
+in grey bars are only from countries reporting hospitalizations or ICU admissions, respectively.  
+ 
+ 
+16 
+ Severity indicators  
+ 
+The IC"
+" interpret ed with caution. Cases included 
+in grey bars are only from countries reporting hospitalizations or ICU admissions, respectively.  
+ 
+ 
+16 
+ Severity indicators  
+ 
+The ICU -to-hospitalization ratio and death -to-hospitalization ratio have been key indicators for understanding 
+COVID -19 severity throughout the pandemic. The ICU -to-hospitalization ratio is used"
+"U -to-hospitalization ratio and death -to-hospitalization ratio have been key indicators for understanding 
+COVID -19 severity throughout the pandemic. The ICU -to-hospitalization ratio is used to assess the proportion of 
+patients requiring ICU admission in relation to the total number of hospitalizations. The death -to-hospitalization ratio 
+is used to assess the proportion of death s in relation to hospitalized patients"
+"to assess the proportion of 
+patients requiring ICU admission in relation to the total number of hospitalizations. The death -to-hospitalization ratio 
+is used to assess the proportion of death s in relation to hospitalized patients.  
+ 
+These indicators are subject to the same limitations mentioned above and their calculations are limited to the 
+countries reporting all relevant data elements (hospitalizations , ICU admissions and deaths) in a given reporting"
+".  
+ 
+These indicators are subject to the same limitations mentioned above and their calculations are limited to the 
+countries reporting all relevant data elements (hospitalizations , ICU admissions and deaths) in a given reporting 
+period . It should be noted that there may be differences in reporting among countries. For instance, in some 
+countries, hospitalization data may include ICU admissions, whereas in others, ICU admissions may be reported "
+"
+period . It should be noted that there may be differences in reporting among countries. For instance, in some 
+countries, hospitalization data may include ICU admissions, whereas in others, ICU admissions may be reported 
+separately. Furthermore, it is important to  consider that some death s might have occurred outside of hospital 
+facilities.  
+ 
+Overall, the ICU -to-hospitalization ratio has been decreasing since the"
+"
+separately. Furthermore, it is important to  consider that some death s might have occurred outside of hospital 
+facilities.  
+ 
+Overall, the ICU -to-hospitalization ratio has been decreasing since the peak in July 2021 when the ratio was 0.2 6, 
+dropping below 0.15 since the beginning of 2022, and around 0.05 since the start of"
+"peak in July 2021 when the ratio was 0.2 6, 
+dropping below 0.15 since the beginning of 2022, and around 0.05 since the start of 2023  (Figure 8) . The trend has 
+been stable  in recent wee ks. This suggests that a decreasing proportion of new hospitalizations require intensive 
+care.  
+"
+"2023  (Figure 8) . The trend has 
+been stable  in recent wee ks. This suggests that a decreasing proportion of new hospitalizations require intensive 
+care.  
+ 
+Similarly, the death -to-hospitalization ratio has been showing a general decline since July 2021. Since January 2023, 
+it has remained under 0.15 ,"
+"
+Similarly, the death -to-hospitalization ratio has been showing a general decline since July 2021. Since January 2023, 
+it has remained under 0.15 , varying  between 0.06 to 0.14. This is an encouraging trend indicating a lower mortality 
+risk among hospitalized individuals.  
+ 
+Please n ote that the causes for these decre"
+"varying  between 0.06 to 0.14. This is an encouraging trend indicating a lower mortality 
+risk among hospitalized individuals.  
+ 
+Please n ote that the causes for these decreases cannot be directly interpreted from these data, but likely include a 
+combination of increases in infection -derived or vaccine -derived immunity, improvements in early diagnosis and 
+clinical care, reduced"
+"ases cannot be directly interpreted from these data, but likely include a 
+combination of increases in infection -derived or vaccine -derived immunity, improvements in early diagnosis and 
+clinical care, reduced strain on hea lth systems, and other factors. It is not possible to infer a decreased intrinsic 
+virulence amongst newer SARS -CoV-2 variants from these data.  
+ 
+ 
+"
+"strain on hea lth systems, and other factors. It is not possible to infer a decreased intrinsic 
+virulence amongst newer SARS -CoV-2 variants from these data.  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+17 
+ Figure 8. COVID -19"
+"
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+17 
+ Figure 8. COVID -19 ICU -to-hospitalization ratio and death -to-hospitalization ratio, from 27 April  2020 to  7 January 
+2023  (A), and 22 May  to"
+"ICU -to-hospitalization ratio and death -to-hospitalization ratio, from 27 April  2020 to  7 January 
+2023  (A), and 22 May  to 7 January  2024 (B) 
+ 
+A 
+ 
+ 
+B 
+ 
+ 
+ 
+ 
+ 
+Note: Recent weeks are subject to reporting delays and should not be"
+"7 January  2024 (B) 
+ 
+A 
+ 
+ 
+B 
+ 
+ 
+ 
+ 
+ 
+Note: Recent weeks are subject to reporting delays and should not be interpreted as a declining trend. The ICU ratio figure is created from the data of the countries 
+reported both new hospitalizations and new ICU admissions. The d eath ratio figure is created from the data of the countries"
+"interpreted as a declining trend. The ICU ratio figure is created from the data of the countries 
+reported both new hospitalizations and new ICU admissions. The d eath ratio figure is created from the data of the countries that reported both new hospitalization 
+and new deaths.  
+Source : WHO COVID -19 Detailed Surveillance Dashboard  
+ 
+18 
+ SARS -CoV-2 variants of"
+"that reported both new hospitalization 
+and new deaths.  
+Source : WHO COVID -19 Detailed Surveillance Dashboard  
+ 
+18 
+ SARS -CoV-2 variants of interest  and variants under monitoring  
+ 
+Geographic spread and prevalence  
+Globally, during the 28 -day period from 11 December 2023 to 7 January 2024"
+"interest  and variants under monitoring  
+ 
+Geographic spread and prevalence  
+Globally, during the 28 -day period from 11 December 2023 to 7 January 2024, 33 659 SARS -CoV-2 sequences were 
+shared through GISAID. In comparison, in the two previous 28 -day periods, there were 112 90"
+", 33 659 SARS -CoV-2 sequences were 
+shared through GISAID. In comparison, in the two previous 28 -day periods, there were 112 909 and 192 222 
+sequences shared, respectively. The data are periodically retrospectively updated to include sequences w ith earlier 
+collection dates, so the number of submissions in a given time"
+"9 and 192 222 
+sequences shared, respectively. The data are periodically retrospectively updated to include sequences w ith earlier 
+collection dates, so the number of submissions in a given time period may change.  
+ 
+WHO is currently tracking several SARS -CoV-2 variants, including:  
+•  Five variants of interest (VOIs): XBB.1.5, XBB.1."
+"period may change.  
+ 
+WHO is currently tracking several SARS -CoV-2 variants, including:  
+•  Five variants of interest (VOIs): XBB.1.5, XBB.1.16, EG.5, BA.2.86 and JN.1  
+•  Five variants under monitoring (VUMs): DV.7, XBB, XBB.1.9.1,"
+"16, EG.5, BA.2.86 and JN.1  
+•  Five variants under monitoring (VUMs): DV.7, XBB, XBB.1.9.1, XBB.1.9.2 and XBB.2.3  
+ 
+Table 6 shows the number of countries reporting VOIs and VUMs, and their prevalence from epidemiological week 
+4"
+"XBB.1.9.2 and XBB.2.3  
+ 
+Table 6 shows the number of countries reporting VOIs and VUMs, and their prevalence from epidemiological week 
+48 (27 November to 3 December 2023) to week 52 (25 December to 31 December 2023). The VOIs and VUMs 
+exhibiting increasing tr"
+"8 (27 November to 3 December 2023) to week 52 (25 December to 31 December 2023). The VOIs and VUMs 
+exhibiting increasing trends are highlighted i n yellow, those that have remained stable are highlighted in blue, and 
+those with decreasing trends are highlighted in green.  
+ 
+Globally, JN.1 is currently the"
+"ends are highlighted i n yellow, those that have remained stable are highlighted in blue, and 
+those with decreasing trends are highlighted in green.  
+ 
+Globally, JN.1 is currently the dominant circulating  VOI (reported by 71 countries), accounting for 65.5% of sequences 
+in week 52 compared to 24.8% in week 48 (Figure"
+"dominant circulating  VOI (reported by 71 countries), accounting for 65.5% of sequences 
+in week 52 compared to 24.8% in week 48 (Figure 10, Table 6). Its parent lineage, BA.2.86, is stable and accounted 
+for 7.8% of sequences in week 52 compared to 7.0% in week"
+"10, Table 6). Its parent lineage, BA.2.86, is stable and accounted 
+for 7.8% of sequences in week 52 compared to 7.0% in week 48 (Figure 10, Table 6 ). The initial risk evaluation for 
+JN.1  was published on 19 December 2023, with an overall evaluation of low public health risk at the"
+"48 (Figure 10, Table 6 ). The initial risk evaluation for 
+JN.1  was published on 19 December 2023, with an overall evaluation of low public health risk at the global level 
+based on available evidence.  
+ 
+The other VOIs, XBB.1.5, XBB.1.16 and EG.5, have decreased in global prevalence during the same"
+"global level 
+based on available evidence.  
+ 
+The other VOIs, XBB.1.5, XBB.1.16 and EG.5, have decreased in global prevalence during the same period: XBB.1.5 
+accounted for 3.3% of sequences in week 52, a decrease from 8.3% in week 48; XBB.1.6 accounted for "
+"period: XBB.1.5 
+accounted for 3.3% of sequences in week 52, a decrease from 8.3% in week 48; XBB.1.6 accounted for 1.5% of 
+sequences in week 52, a decrease from  6.3% in week 48; EG.5 accounted for 16.6% of sequences in week 52,"
+"1.5% of 
+sequences in week 52, a decrease from  6.3% in week 48; EG.5 accounted for 16.6% of sequences in week 52, a 
+decrease from 43.6% in week 48 (Figure 10, Table 6).  
+ 
+All VUMs have shown a decreasing trend over the reporting period (Table"
+"a 
+decrease from 43.6% in week 48 (Figure 10, Table 6).  
+ 
+All VUMs have shown a decreasing trend over the reporting period (Table 6).  
+ 
+Sufficient sequencing data to calculate variant prevalence at the regional level during weeks 48 to 52 were available 
+from four WHO regions: the Region of the Americas, the Western"
+"6).  
+ 
+Sufficient sequencing data to calculate variant prevalence at the regional level during weeks 48 to 52 were available 
+from four WHO regions: the Region of the Americas, the Western Pacific Region, the South -East Asia Region, and the 
+European Region (Table 7). Among the VOIs, JN.1 was the most reported variant and showing an increasing trend in 
+all the four"
+"Pacific Region, the South -East Asia Region, and the 
+European Region (Table 7). Among the VOIs, JN.1 was the most reported variant and showing an increasing trend in 
+all the four regions. Except for XBB.1.16 that showed a small increase in the Western Pacific Region, the other VOIs 
+and all the VUMs in all four regions observed dec reasing or stable trends.  "
+"regions. Except for XBB.1.16 that showed a small increase in the Western Pacific Region, the other VOIs 
+and all the VUMs in all four regions observed dec reasing or stable trends.  
+ 
+With declining rates of testing and sequencing globally (Figure 10), it is increasingly challenging to estimate the 
+severity impact of emerging SARS -CoV-2 variants. There"
+"
+ 
+With declining rates of testing and sequencing globally (Figure 10), it is increasingly challenging to estimate the 
+severity impact of emerging SARS -CoV-2 variants. There are currently no reported laboratory or epidemiological 
+reports indicating any associ ation between VOIs/VUMs and increased disease severity. As shown in Figure 9 and 
+Figure 10, low"
+"are currently no reported laboratory or epidemiological 
+reports indicating any associ ation between VOIs/VUMs and increased disease severity. As shown in Figure 9 and 
+Figure 10, low and unrepresentative levels of SARS -CoV-2 genomic surveillance continue to pose challenges in 
+adequately assessing the variant landscape.  
+ 
+ 
+ 
+ 
+ 
+ "
+"and unrepresentative levels of SARS -CoV-2 genomic surveillance continue to pose challenges in 
+adequately assessing the variant landscape.  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+19 
+ Table 6. Weekly prevalence of SARS -CoV-2 VOIs and VUMs, week 48 to week 52 of "
+"
+ 
+ 
+ 
+  
+19 
+ Table 6. Weekly prevalence of SARS -CoV-2 VOIs and VUMs, week 48 to week 52 of 202 4 
+ 
+ 
+ 
+§ Number of countries and sequences are since the emergence of the variants.  
+* Includes descendant lineages, except those individually specified elsewhere in the table. For example,"
+"202 4 
+ 
+ 
+ 
+§ Number of countries and sequences are since the emergence of the variants.  
+* Includes descendant lineages, except those individually specified elsewhere in the table. For example, XBB* does not includ e 
+XBB.1.5, XBB.1.16, EG.5, XBB.1.9.1, XBB.1.9.2, and XBB"
+"XBB* does not includ e 
+XBB.1.5, XBB.1.16, EG.5, XBB.1.9.1, XBB.1.9.2, and XBB.2.3.  
+ 
+ 
+Table 7. Weekly prevalence of SARS -CoV-2 VOIs and VUMs by WHO regions, week 48 to week 52"
+".2.3.  
+ 
+ 
+Table 7. Weekly prevalence of SARS -CoV-2 VOIs and VUMs by WHO regions, week 48 to week 52 of 2023  
+ 
+ 
+ 
+* Includes descendant lineages, except those individually specified elsewhere in the table. For example, XBB* does not includ e 
+XBB.1.5,"
+"of 2023  
+ 
+ 
+ 
+* Includes descendant lineages, except those individually specified elsewhere in the table. For example, XBB* does not includ e 
+XBB.1.5, XBB.1.16, EG.5, XBB.1.9.1, XBB.1.9.2, and XBB.2.3.  
+¥ due to the small numbers of sequences submitted"
+"XBB.1.16, EG.5, XBB.1.9.1, XBB.1.9.2, and XBB.2.3.  
+¥ due to the small numbers of sequences submitted in these regions, it has not been possible to determine trends for the VOIs  and 
+VUMs in these regions; this is also represented by the shaded cells in the table .   
+ 
+ 
+20"
+"in these regions, it has not been possible to determine trends for the VOIs  and 
+VUMs in these regions; this is also represented by the shaded cells in the table .   
+ 
+ 
+20 
+ Figure 9. Global 28 -day prevalence of EG.5, XBB.1.5, XBB.1.16, BA.2.86, and JN.1,"
+"
+ Figure 9. Global 28 -day prevalence of EG.5, XBB.1.5, XBB.1.16, BA.2.86, and JN.1, from 11 December 2023 to 7 January  
+2024  *+     
+ 
+ 
+* Reporting period to account for delay in sequence submission to GISAID.  
++ Historical"
+"from 11 December 2023 to 7 January  
+2024  *+     
+ 
+ 
+* Reporting period to account for delay in sequence submission to GISAID.  
++ Historical presence indicates countries previously reporting sequences of VOIs but have not reported within the period from 4 
+November  to 3 December  2023  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+"
+"presence indicates countries previously reporting sequences of VOIs but have not reported within the period from 4 
+November  to 3 December  2023  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+21 
+ Figure 10. The (A) number and (B) percentage of"
+"
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+21 
+ Figure 10. The (A) number and (B) percentage of SARS -CoV-2 sequences, from 3 July to 31 December  2023  
+ 
+ 
+ 
+ 
+ 
+ 
+   
+Figure 10. Panel A "
+"SARS -CoV-2 sequences, from 3 July to 31 December  2023  
+ 
+ 
+ 
+ 
+ 
+ 
+   
+Figure 10. Panel A  shows the number, and Panel B  the percentage, of all circulating variants since July to December 2023. The variants 
+shown here include descendent lineages, except for the descendent lineage(s)"
+"shows the number, and Panel B  the percentage, of all circulating variants since July to December 2023. The variants 
+shown here include descendent lineages, except for the descendent lineage(s) listed here. The Unassigned category includes lineages 
+pending for a PANGO lineage name designation, whereas the Other category includes lineages that are assigned but not listed here. 
+Source: SARS -Co"
+"listed here. The Unassigned category includes lineages 
+pending for a PANGO lineage name designation, whereas the Other category includes lineages that are assigned but not listed here. 
+Source: SARS -CoV-2 sequence data and metadata from GISAID, from 3 July to 31 December 2023.  
+ 
+ 
+ 
+ 
+A 
+B  
+22 
+ Additional"
+"V-2 sequence data and metadata from GISAID, from 3 July to 31 December 2023.  
+ 
+ 
+ 
+ 
+A 
+B  
+22 
+ Additional resources  
+ 
+• Tracking SARS -CoV-2 Variants  
+• WHO statement on updated tracking system on SARS -CoV-2 variants of concern and variants of interest   
+• SARS"
+"resources  
+ 
+• Tracking SARS -CoV-2 Variants  
+• WHO statement on updated tracking system on SARS -CoV-2 variants of concern and variants of interest   
+• SARS -CoV-2 variant risk evaluation framework, 30 August 2023  
+• WHO JN.1 Initial Risk Evaluation, 1 3 December 2023  
+• WHO"
+"-CoV-2 variant risk evaluation framework, 30 August 2023  
+• WHO JN.1 Initial Risk Evaluation, 1 3 December 2023  
+• WHO BA.2.86 Initial Risk Evaluation, 21 November 2023  
+• WHO EG.5 Updated Risk Evaluation, 21 November 2023  
+"
+"BA.2.86 Initial Risk Evaluation, 21 November 2023  
+• WHO EG.5 Updated Risk Evaluation, 21 November 2023  
+• WHO XBB.1.5 Updated Risk Assessment, 20 June 2023  
+• WHO XBB.1.16 Updated Risk Assessment, 5 June 20"
+"• WHO XBB.1.5 Updated Risk Assessment, 20 June 2023  
+• WHO XBB.1.16 Updated Risk Assessment, 5 June 2023    
+22 WHO  regional  overviews   
+Data for 11 December  2023  to 7 January 2024  
+ 
+African  Region 
+The African Region"
+"23    
+22 WHO  regional  overviews   
+Data for 11 December  2023  to 7 January 2024  
+ 
+African  Region 
+The African Region reported over 3354 new cases, a 63% decrease as compared to the previous 28 -day period. Five (10%) of the 50 countries for which data are 
+available reported increases in new"
+"reported over 3354 new cases, a 63% decrease as compared to the previous 28 -day period. Five (10%) of the 50 countries for which data are 
+available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Mauritania ( 30 vs six new cases; +400%), Senegal 
+(17 vs six new cases ; +18"
+"cases of 20% or greater, with the highest proportional increases observed in Mauritania ( 30 vs six new cases; +400%), Senegal 
+(17 vs six new cases ; +183%), Mali (two vs one new case; +100%), Burundi (78 vs 51 new cases; +53%), and Angola (417 vs 316 new cases"
+"3%), Mali (two vs one new case; +100%), Burundi (78 vs 51 new cases; +53%), and Angola (417 vs 316 new cases; +32%). The  highest 
+numbers of new cases were reported from Mauritius (3228 new cases; 253.8 new cases per 100 000; -57%"
+"; +32%). The  highest 
+numbers of new cases were reported from Mauritius (3228 new cases; 253.8 new cases per 100 000; -57%), Angola (417 new cas es; 1.3 new cases per 100 000; 
++32%), and Burundi (78 new cases; <1 new case per "
+"), Angola (417 new cas es; 1.3 new cases per 100 000; 
++32%), and Burundi (78 new cases; <1 new case per 100 000; +53%).  
+The number of new 28 -day deaths in the Region decreased by 113% as compared to the previous 28 -day period, with no"
+"100 000; +53%).  
+The number of new 28 -day deaths in the Region decreased by 113% as compared to the previous 28 -day period, with no new deaths reported. The highest numbers 
+of new deaths were reported from Mauritius (1 new death; <1 new death per 100 000; -50%), and Namibi a ("
+"new deaths reported. The highest numbers 
+of new deaths were reported from Mauritius (1 new death; <1 new death per 100 000; -50%), and Namibi a (1 new death; <1 new death per 100 000; -67%).  
+ 
+ 
+Updates from the  African Region  
+ 
+22 Region  of the Americas   
+The"
+"1 new death; <1 new death per 100 000; -67%).  
+ 
+ 
+Updates from the  African Region  
+ 
+22 Region  of the Americas   
+The Region of the Americas reported over 42 000 new cases, an 18% decrease as compared to the previous 28 -day period. Seven (12%) of the 56 countries for 
+which"
+"Region of the Americas reported over 42 000 new cases, an 18% decrease as compared to the previous 28 -day period. Seven (12%) of the 56 countries for 
+which data are available reported increases in new cases of 20% or greater, with the highest proportio nal increases observed in Panama (822 vs 180 new cases; 
++357%), Barbados"
+"data are available reported increases in new cases of 20% or greater, with the highest proportio nal increases observed in Panama (822 vs 180 new cases; 
++357%), Barbados (33 vs 14 new cases; +136%), Plurinational State of Bolivia  (1563 vs 670 new cases; +133%), Guyana (six vs three"
+"(33 vs 14 new cases; +136%), Plurinational State of Bolivia  (1563 vs 670 new cases; +133%), Guyana (six vs three new cases; +100%), Colombia 
+(1 680 vs 1 266 new cases; +33%), Paraguay (92 vs 73 new cases; +26%"
+"new cases; +100%), Colombia 
+(1 680 vs 1 266 new cases; +33%), Paraguay (92 vs 73 new cases; +26%), and Jamaica (32 vs 26 new cases; +23%). The highest numbers of new cases were reported 
+from Canada (18 947 new cases; 50.2 new cases per "
+"), and Jamaica (32 vs 26 new cases; +23%). The highest numbers of new cases were reported 
+from Canada (18 947 new cases; 50.2 new cases per 100 000; -18%), Chile (9693 new cases; 50.7 new cases per 100 000; -25%), and Peru (465"
+"100 000; -18%), Chile (9693 new cases; 50.7 new cases per 100 000; -25%), and Peru (4657 new cases; 14.1 
+new cases per 100 000; -38%).  
+The number of new 28 -day deaths in the Region decreased by 41%"
+"7 new cases; 14.1 
+new cases per 100 000; -38%).  
+The number of new 28 -day deaths in the Region decreased by 41% as compared to the previous 28 -day period, with 3869 new deaths reported. The highest 
+numbers of new deaths were reported from the United States of America (3552 new deaths; "
+"as compared to the previous 28 -day period, with 3869 new deaths reported. The highest 
+numbers of new deaths were reported from the United States of America (3552 new deaths; 1.1 new deaths per 100 000; -40%), Canada (128 new deaths; <1 new 
+death per 100 000; -60"
+"1.1 new deaths per 100 000; -40%), Canada (128 new deaths; <1 new 
+death per 100 000; -60%), and Chile (114 new deaths; <1 new death per 100 000; -46%).  
+ 
+ 
+ 
+ 
+Updates from the  Region of the Americas"
+"%), and Chile (114 new deaths; <1 new death per 100 000; -46%).  
+ 
+ 
+ 
+ 
+Updates from the  Region of the Americas
+ 
+  23 Eastern  Mediterranean  Region  
+The Eastern Mediterranean Region reported over 2464 new cases, a 13% decrease as compared to the previous 28 -day period. One"
+"
+ 
+  23 Eastern  Mediterranean  Region  
+The Eastern Mediterranean Region reported over 2464 new cases, a 13% decrease as compared to the previous 28 -day period. One (5%) of the 22 countries for 
+which data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Kuwait (102 vs 39 new cases;"
+"(5%) of the 22 countries for 
+which data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Kuwait (102 vs 39 new cases; 
++162%). The highest numbers of new cases were reported from Afghanistan (1256 new cas es; 3.2 new cases per 100 000; +14%), the Islam"
+"
++162%). The highest numbers of new cases were reported from Afghanistan (1256 new cas es; 3.2 new cases per 100 000; +14%), the Islamic Republic of Iran (663 
+new cases; <1 new case per 100 000; -48%), and Morocco (443 new cases; 1.2 new cases per"
+"ic Republic of Iran (663 
+new cases; <1 new case per 100 000; -48%), and Morocco (443 new cases; 1.2 new cases per 100 000; +6%).  
+The number of new 28 -day deaths in the Region decreased by 53% as compared to the previous 28 -day period, with 3"
+"100 000; +6%).  
+The number of new 28 -day deaths in the Region decreased by 53% as compared to the previous 28 -day period, with 37 new deaths reported. The highest numbers 
+of new deaths were reported from the Islamic Republic of Iran (27 new deaths; <1 new death per 100 00 0; -63%"
+"7 new deaths reported. The highest numbers 
+of new deaths were reported from the Islamic Republic of Iran (27 new deaths; <1 new death per 100 00 0; -63%), Afghanistan (8 new deaths; <1 new death per 
+100 000; +60%), and Morocco (2 new deaths; <1 new death per 100 0"
+"), Afghanistan (8 new deaths; <1 new death per 
+100 000; +60%), and Morocco (2 new deaths; <1 new death per 100 000; +100%).  
+ 
+Updates  from  the Eastern  Mediterranean  Region  
+ 
+ 
+ 
+ 
+ 
+  23 European Region  
+The European Region reported over "
+"00; +100%).  
+ 
+Updates  from  the Eastern  Mediterranean  Region  
+ 
+ 
+ 
+ 
+ 
+  23 European Region  
+The European Region reported over 701 000 new cases, a 13% decrease as compared to the previous 28 -day period. 10 (16%) of the 62 countries for which data 
+are available reported increases"
+"701 000 new cases, a 13% decrease as compared to the previous 28 -day period. 10 (16%) of the 62 countries for which data 
+are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Malta (310 vs 75 new cases; +313%), Republic 
+of Moldova (2 951 vs"
+"in new cases of 20% or greater, with the highest proportional increases observed in Malta (310 vs 75 new cases; +313%), Republic 
+of Moldova (2 951 vs 1 485 new cases; +99%), Ireland (3 433 vs 1 856 new cases; +85%), Greece (68 590 vs 37 9"
+"1 485 new cases; +99%), Ireland (3 433 vs 1 856 new cases; +85%), Greece (68 590 vs 37 925 new cases; +81%), the United Kingdom (37 787 vs 
+22 791 new cases; +66%), Romania (7 380 vs 4 9"
+"25 new cases; +81%), the United Kingdom (37 787 vs 
+22 791 new cases; +66%), Romania (7 380 vs 4 916 new cases; +50%), Portugal (4 451 vs 3 103 new cases; +43%), Belgium (10 653 vs 8 623 new cases"
+"16 new cases; +50%), Portugal (4 451 vs 3 103 new cases; +43%), Belgium (10 653 vs 8 623 new cases; +24%), 
+Luxembourg (2 054 vs 1 696 new cases; +21%), and Netherlands (5 330 vs 4 442 new cases"
+"; +24%), 
+Luxembourg (2 054 vs 1 696 new cases; +21%), and Netherlands (5 330 vs 4 442 new cases; +20%). The highest numbers of new cases were reported from the 
+Russian Federation (235 198 new cases; 161.2 new cases per 100 000; -"
+"; +20%). The highest numbers of new cases were reported from the 
+Russian Federation (235 198 new cases; 161.2 new cases per 100 000; -30%), Italy (163 599 new cases; 274.3 new cases per 100 000; -18%), and Greece (68 590 
+"
+"30%), Italy (163 599 new cases; 274.3 new cases per 100 000; -18%), and Greece (68 590 
+new cases; 639.9 new c ases per 100 000; +81%).  
+The number of new 28 -day deaths in the Region decreased by 3% as compared"
+"new cases; 639.9 new c ases per 100 000; +81%).  
+The number of new 28 -day deaths in the Region decreased by 3% as compared to the previous 28 -day period, with 4194 new deaths reported. The highest numbers 
+of new deaths were reported from Italy (1016 new deaths; 1.7 new deaths"
+"to the previous 28 -day period, with 4194 new deaths reported. The highest numbers 
+of new deaths were reported from Italy (1016 new deaths; 1.7 new deaths per 100 000; -21%), the Russ ian Federation (679 new deaths; <1 new death per 100 
+000; +45%), and Poland"
+"per 100 000; -21%), the Russ ian Federation (679 new deaths; <1 new death per 100 
+000; +45%), and Poland (543 new deaths; 1.4 new deaths per 100 000; +229%).  
+ 
+ 
+ 
+ 
+Updates  from  the European  Region
+"
+"(543 new deaths; 1.4 new deaths per 100 000; +229%).  
+ 
+ 
+ 
+ 
+Updates  from  the European  Region
+ 
+25 
+ South -East  Asia  Region  
+The South -East Asia Region reported over 26 000 new cases, a 379% increase as compared to the previous 28"
+"
+25 
+ South -East  Asia  Region  
+The South -East Asia Region reported over 26 000 new cases, a 379% increase as compared to the previous 28 -day period. Five (45%) of the 11 countries for which 
+data are available reported increases in new cases of 20% or greater, with the highest proportion al increases observed in India (15 07"
+"-day period. Five (45%) of the 11 countries for which 
+data are available reported increases in new cases of 20% or greater, with the highest proportion al increases observed in India (15 079 vs 1 599 new cases; +843%), 
+Myanmar (110 vs 20 new cases; +450%), Indonesia (8 610 vs 1"
+"9 vs 1 599 new cases; +843%), 
+Myanmar (110 vs 20 new cases; +450%), Indonesia (8 610 vs 1 727 new cases; +399%), Bangladesh (276 vs 141 new cases; +96%), and Sri Lanka (67 vs 42 new 
+cases; +"
+"727 new cases; +399%), Bangladesh (276 vs 141 new cases; +96%), and Sri Lanka (67 vs 42 new 
+cases; +60%). The highest numbers of new cases were reported from India (15 079 new cases; 1.1 new cases per 100 000; +843%),  Indonesia (8"
+"60%). The highest numbers of new cases were reported from India (15 079 new cases; 1.1 new cases per 100 000; +843%),  Indonesia (8610 new cases; 3.1 
+new cas es per 100 000; +399%), and Thailand (2327 new cases; 3.3 new cases per "
+"610 new cases; 3.1 
+new cas es per 100 000; +399%), and Thailand (2327 new cases; 3.3 new cases per 100 000; +17%).  
+The number of new 28 -day deaths in the Region increased by 564% as compared to the previous 28 -day period, with 1"
+"100 000; +17%).  
+The number of new 28 -day deaths in the Region increased by 564% as compared to the previous 28 -day period, with 186 new deaths reported. The highest 
+numbers of new deaths were reported from India (86 new deaths; <1 new death per 100 000; +682%), Indonesia ("
+"86 new deaths reported. The highest 
+numbers of new deaths were reported from India (86 new deaths; <1 new death per 100 000; +682%), Indonesia (72 new deaths; <1 new death per 100 000; 
++1340%), and Thailand (21 new deaths; <1 new death per 100 0"
+"72 new deaths; <1 new death per 100 000; 
++1340%), and Thailand (21 new deaths; <1 new death per 100 000; +91%).  
+ 
+ 
+ 
+Updates from the South -East Asia Region  
+ 
+26 
+ Western  Pacific  Region  
+The Western Pacific Region reported over 338"
+"00; +91%).  
+ 
+ 
+ 
+Updates from the South -East Asia Region  
+ 
+26 
+ Western  Pacific  Region  
+The Western Pacific Region reported over 338 000 new cases, a 77% increase as compared to the previous 28 -day period. Ten (29%) of the 35 countries for which 
+data are available reported increases in new cases of "
+"000 new cases, a 77% increase as compared to the previous 28 -day period. Ten (29%) of the 35 countries for which 
+data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Niu e (98 vs six new cases; +1533%), Palau 
+(16 vs two new cases; +700%), T"
+"20% or greater, with the highest proportional increases observed in Niu e (98 vs six new cases; +1533%), Palau 
+(16 vs two new cases; +700%), Tonga (62 vs 12 new cases ; +417%), Cook Islands (29 vs six new cases; +383%), Cambodia (76 vs 16 new cases; +375"
+"onga (62 vs 12 new cases ; +417%), Cook Islands (29 vs six new cases; +383%), Cambodia (76 vs 16 new cases; +375%), Brunei 
+Darussalam (16 648 vs 4 207 new cases; +296%), Malaysia (67 206 vs 25 4"
+"%), Brunei 
+Darussalam (16 648 vs 4 207 new cases; +296%), Malaysia (67 206 vs 25 484 new cases; +164%), the Philippines (10 262 vs 4 672 new cases; +120%), Singapore 
+(174 643 vs 8"
+"84 new cases; +164%), the Philippines (10 262 vs 4 672 new cases; +120%), Singapore 
+(174 643 vs 80 296 new cases; +117%), and China (2 514 vs 1 674 new cases; +50%). The highest numbers of new cases were repor ted from Singapore (1"
+"0 296 new cases; +117%), and China (2 514 vs 1 674 new cases; +50%). The highest numbers of new cases were repor ted from Singapore (174 643 
+new cases; 2985.2 new cases per 100 000; +117%), Malaysia (67 206 new cases; 2"
+"74 643 
+new cases; 2985.2 new cases per 100 000; +117%), Malaysia (67 206 new cases; 207.6 new cases per 100 000; +164%), and Australia (41 965 new cases; 164.6 
+new cases per 100 "
+"07.6 new cases per 100 000; +164%), and Australia (41 965 new cases; 164.6 
+new cases per 100 000; -18%).  
+The number of new 28 -day deaths in the Region decreased by 45% as compared to the previous 28 -day period, with 416 new death"
+"000; -18%).  
+The number of new 28 -day deaths in the Region decreased by 45% as compared to the previous 28 -day period, with 416 new deaths reported. The highest numbers 
+of new deaths were reported from Australia (185 new deaths; <1 new death per 100 000; -67%), Malaysi a (97 new"
+"s reported. The highest numbers 
+of new deaths were reported from Australia (185 new deaths; <1 new death per 100 000; -67%), Malaysi a (97 new deaths; <1 new death per 100 000; +259%), 
+and New Zealand (54 new deaths; 1.1 new deaths per 100 00"
+"deaths; <1 new death per 100 000; +259%), 
+and New Zealand (54 new deaths; 1.1 new deaths per 100 000; -49%).  
+ 
+ 
+Updates from the Western Pacific Region  
+ 
+25 
+ Annex 1. Data, table, and figure notes  
+Data presented are based on official laboratory -"
+"0; -49%).  
+ 
+ 
+Updates from the Western Pacific Region  
+ 
+25 
+ Annex 1. Data, table, and figure notes  
+Data presented are based on official laboratory -confirmed COVID -19 cases and deaths reported to WHO by 
+coun try/territories/areas, largely based upon WHO case definitions  and surveillance guidance . While steps are taken to 
+"
+"confirmed COVID -19 cases and deaths reported to WHO by 
+coun try/territories/areas, largely based upon WHO case definitions  and surveillance guidance . While steps are taken to 
+ensure accuracy and reliability, all data are subject to continuous verification and change, and caution must be taken when 
+interpreting these data as several factors influence the counts presented, with variable underestimation o f true case and "
+"ensure accuracy and reliability, all data are subject to continuous verification and change, and caution must be taken when 
+interpreting these data as several factors influence the counts presented, with variable underestimation o f true case and 
+death incidences, and variable delays to reflecting these data at the global level. Case detection, inclusion criteria, testi ng 
+strategies, reporting practices, and data cut -off and lag times differ between countries"
+"
+death incidences, and variable delays to reflecting these data at the global level. Case detection, inclusion criteria, testi ng 
+strategies, reporting practices, and data cut -off and lag times differ between countries/territories/areas.  Dif ferences are 
+to be expected between information products published by WHO, national public health authorities, and other sources.  
+A record of historic data adjustment is available upon request by"
+"/territories/areas.  Dif ferences are 
+to be expected between information products published by WHO, national public health authorities, and other sources.  
+A record of historic data adjustment is available upon request by emailing epi-data [email protected] . Please specify the 
+countries of interest, time period, and purpose of the request/intended usage. Prior situation reports will not be edited; 
+see covid1"
+"emailing epi-data [email protected] . Please specify the 
+countries of interest, time period, and purpose of the request/intended usage. Prior situation reports will not be edited; 
+see covid19.who.int  for the most up -to-date data.  
+‘Countries’ may refer to countries, territories, areas or other jurisdictions of similar status. The  designations employed, 
+and the"
+"9.who.int  for the most up -to-date data.  
+‘Countries’ may refer to countries, territories, areas or other jurisdictions of similar status. The  designations employed, 
+and the presentation of these materials , do not imply the expression of any opinion whatsoever on the part of WHO 
+concerning the legal status of any country, territory, or area or of its authorities, or concerning the delimitation"
+"presentation of these materials , do not imply the expression of any opinion whatsoever on the part of WHO 
+concerning the legal status of any country, territory, or area or of its authorities, or concerning the delimitation of its 
+frontiers or boundaries. Dotted and dashed lines on maps r epresent approximate border lines for which there may not 
+yet be full agreement. Countries, territories, and areas are arranged under the administering"
+"of its 
+frontiers or boundaries. Dotted and dashed lines on maps r epresent approximate border lines for which there may not 
+yet be full agreement. Countries, territories, and areas are arranged under the administering WHO region. The mention 
+of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by 
+WHO in preference to others of a similar nature that are not mentioned. Errors"
+"WHO region. The mention 
+of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by 
+WHO in preference to others of a similar nature that are not mentioned. Errors and omissions  excepted;  the names of 
+proprietary products are distinguished by initial capital letters.  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ "
+"and omissions  excepted;  the names of 
+proprietary products are distinguished by initial capital letters.  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+26 
+ Annex 2. SARS -CoV-2 variants assessment and classification  
+ 
+WHO,"
+"
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+  
+26 
+ Annex 2. SARS -CoV-2 variants assessment and classification  
+ 
+WHO, in collaboration with national authorities, institutions and researchers, routinely assesses if variants of SARS -
+CoV-2 alter transmission or disease characteristics, or impact the effectiveness of vaccines, therapeutics,"
+"in collaboration with national authorities, institutions and researchers, routinely assesses if variants of SARS -
+CoV-2 alter transmission or disease characteristics, or impact the effectiveness of vaccines, therapeutics, diagnostics 
+or public health a nd social measures (PHSM) applied to control disease spread. Potential variants of concern (VOCs), 
+variants of interest (VOIs) or variants under monitoring (VUM"
+"diagnostics 
+or public health a nd social measures (PHSM) applied to control disease spread. Potential variants of concern (VOCs), 
+variants of interest (VOIs) or variants under monitoring (VUMs) are regularly assessed based on the risk posed to 
+global public health.  
+ 
+The classifications of variants will be revised as needed to reflect the continuous evolution of circulating variants and 
+their changing ep"
+"s) are regularly assessed based on the risk posed to 
+global public health.  
+ 
+The classifications of variants will be revised as needed to reflect the continuous evolution of circulating variants and 
+their changing epidemiology. Criteria for variant classification, and the lists of currently circulating and previously 
+circulating VO Cs, VOIs and VUMs, are available on the WHO Tracking SARS -CoV"
+"idemiology. Criteria for variant classification, and the lists of currently circulating and previously 
+circulating VO Cs, VOIs and VUMs, are available on the WHO Tracking SARS -CoV-2 variants website . National 
+authorities may choose to designate other variants and are strongly encouraged to investigate and report newly 
+emerging variants and their impact.  
+ 
+WHO continues to monitor SARS -Co"
+"-2 variants website . National 
+authorities may choose to designate other variants and are strongly encouraged to investigate and report newly 
+emerging variants and their impact.  
+ 
+WHO continues to monitor SARS -CoV-2 variants, including descendent lineages of VOCs, to track changes in 
+prevalence and viral characteristics. The current trends describing the circulation of Omicron descendent lineages 
+should be interpreted"
+"V-2 variants, including descendent lineages of VOCs, to track changes in 
+prevalence and viral characteristics. The current trends describing the circulation of Omicron descendent lineages 
+should be interpreted with due consi deration of the limitations of current COVID -19 surveillance. These include 
+differences in sequencing capacity and sampling strategies between countries, changes in sampling strategies over 
+time, reductions in"